EUVIMEDEUVIMED entdecken
Crossref

BCKDHA contributes to melanoma progression by promoting the expressions of lipogenic enzymes FASN and ACLY

Yangzi Tian iD, Jingjing Ma, Mengru Wang, Xiuli Yi, Sen Guo, Hao Wang, Hengxiang Zhang, Huina Wang, Yuqi Yang, Baolu Zhang, Juan Du, Qiong Shi und 3 weitere

Experimental Dermatology · 2023

DOI: 10.1111/exd.14865 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Dermatology, 2023. Verfasst von Yangzi Tian und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: ATP Citrate (pro-S)-Lyase, Melanoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The dysregulation of branched‐chain amino acid (BCAA) metabolism and related enzymes has been greatly implicated in the progression of multiple types of cancer, whereas remains far from understood in melanoma. Here, we explored the role of the BCAA metabolism enzyme BCKDHA in melanoma pathogenesis and elucidated the underlying mechanisms. In vitro cell biology experiments and in vivo pre‐clinical mice model experiments were performed to investigate the role of BCKDHA in melanoma progression. RNA sequencing, immunohistochemical/immunofluorescence staining and bioinformatics analysis were used to examine the underlying mechanism. BCKDHA expression was prominently increased in both melanoma tissues and cell lines. The up‐regulation of BCKDHA promoted long‐term tumour cell proliferation, invasion and migration in vitro and tumour growth in vivo. Through RNA‐sequencing technology, it was found that BCKDHA regulated the expressions of lipogenic fatty acid synthase (FASN) and ATP‐citrate lyase (ACLY), which was thereafter proved to mediate the oncogenic role of BCKDHA in melanoma. Our results demonstrate that BCKDHA promotes melanoma progression by regulating FASN and ACLY expressions. Targeting BCKDHA could be exploited as a promising strategy to restrain tumour progression in melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ATP Citrate (pro-S)-LyaseMelanomaAnimalsMiceCell LineCell ProliferationLipogenesisFatty Acid Synthase, Type I

Stichwörter der Autor:innen

ACLYBCKDHAFASNlipogenesismelanoma

Substanzen

ATP Citrate (pro-S)-LyaseFasn protein, mouseFatty Acid Synthase, Type I

Autor:innen und Institutionen

  • Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.

ORCID-Profile: Yangzi Tian

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Tian, Y., Ma, J., Wang, M., Yi, X., Guo, S., Wang, H., Zhang, H., Wang, H., Yang, Y., Zhang, B., Du, J., Shi, Q., Gao, T., Li, C., & Guo, W. (2023). BCKDHA contributes to melanoma progression by promoting the expressions of lipogenic enzymes FASN and ACLY. Experimental Dermatology. https://doi.org/10.1111/exd.14865

Vancouver

Tian Y, Ma J, Wang M, Yi X, Guo S, Wang H, et al. BCKDHA contributes to melanoma progression by promoting the expressions of lipogenic enzymes FASN and ACLY. Experimental Dermatology. 2023. doi:10.1111/exd.14865

BibTeX
@article{Tian2023,
  author = {Tian, Yangzi and Ma, Jingjing and Wang, Mengru and Yi, Xiuli and Guo, Sen and Wang, Hao and Zhang, Hengxiang and Wang, Huina and Yang, Yuqi and Zhang, Baolu and Du, Juan and Shi, Qiong and Gao, Tianwen and Li, Chunying and Guo, Weinan},
  title = {BCKDHA contributes to melanoma progression by promoting the expressions of lipogenic enzymes FASN and ACLY},
  journal = {Experimental Dermatology},
  year = {2023},
  doi = {10.1111/exd.14865}
}
Kostenlos starten →